263 related articles for article (PubMed ID: 30344922)
1. Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin.
Hashizume A; Umemoto S; Yokose T; Nakamura Y; Yoshihara M; Shoji K; Wada S; Miyagi Y; Kishida T; Sasada T
Oncotarget; 2018 Sep; 9(75):34066-34078. PubMed ID: 30344922
[TBL] [Abstract][Full Text] [Related]
2. The prognostic value of expressions of STAT3, PD-L1, and PD-L2 in Ta/T1 urothelial carcinoma before and after BCG treatment.
Civriz AH; Teke K; Akdas EM; Dillioglugil O; Vural C; Yaprak Bayrak B
Urol Oncol; 2023 Dec; 41(12):486.e1-486.e13. PubMed ID: 37690934
[TBL] [Abstract][Full Text] [Related]
3. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.
Kates M; Matoso A; Choi W; Baras AS; Daniels MJ; Lombardo K; Brant A; Mikkilineni N; McConkey DJ; Kamat AM; Svatek RS; Porten SP; Meeks JJ; Lerner SP; Dinney CP; Black PC; McKiernan JM; Anderson C; Drake CG; Bivalacqua TJ
Clin Cancer Res; 2020 Feb; 26(4):882-891. PubMed ID: 31712383
[TBL] [Abstract][Full Text] [Related]
4. Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC).
Delcourt C; Gemival P; Nouhaud FX; Gobet F; Gillibert A; Ferlicot S; Sabourin JC; Irani J; Pfister C
World J Urol; 2020 Jun; 38(6):1517-1524. PubMed ID: 31486884
[TBL] [Abstract][Full Text] [Related]
5. Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
Chevalier MF; Schneider AK; Cesson V; Dartiguenave F; Lucca I; Jichlinski P; Nardelli-Haefliger D; Derré L
Eur Urol; 2018 Nov; 74(5):540-544. PubMed ID: 30033046
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 Expression in High-Risk Non-Muscle-Invasive Bladder Cancer Is Influenced by Intravesical Bacillus Calmette-Guérin (BCG) Therapy.
Maas M; Hilsendecker A; Pertoll A; Stühler V; Walz S; Rausch S; Stenzl A; Tsaur I; Hennenlotter J; Aufderklamm S
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611034
[TBL] [Abstract][Full Text] [Related]
7. Bacillus Calmette-Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer.
Wang Y; Liu J; Yang X; Liu Y; Liu Y; Li Y; Sun L; Yang X; Niu H
Onco Targets Ther; 2018; 11():2891-2899. PubMed ID: 29844686
[TBL] [Abstract][Full Text] [Related]
8. Immunological Hallmarks for Clinical Response to BCG in Bladder Cancer.
Lim CJ; Nguyen PHD; Wasser M; Kumar P; Lee YH; Nasir NJM; Chua C; Lai L; Hazirah SN; Loh JJH; Khor LY; Yeong J; Lim TKH; Low AWX; Albani S; Chong TW; Chew V
Front Immunol; 2020; 11():615091. PubMed ID: 33584702
[TBL] [Abstract][Full Text] [Related]
9. Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.
Vandeveer AJ; Fallon JK; Tighe R; Sabzevari H; Schlom J; Greiner JW
Cancer Immunol Res; 2016 May; 4(5):452-62. PubMed ID: 26921031
[TBL] [Abstract][Full Text] [Related]
10. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
[TBL] [Abstract][Full Text] [Related]
11. The prognostic value of programmed cell death protein ligand 1 in patients with non-muscle-invasive bladder cancer treated with bacille Calmette-Guérin immunotherapy: Current status.
Nowak Ł; Krajewski W; Poterek A; Śliwa A; Zdrojowy R
Arab J Urol; 2020 Jul; 19(1):67-70. PubMed ID: 33763250
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression.
Inman BA; Sebo TJ; Frigola X; Dong H; Bergstralh EJ; Frank I; Fradet Y; Lacombe L; Kwon ED
Cancer; 2007 Apr; 109(8):1499-505. PubMed ID: 17340590
[TBL] [Abstract][Full Text] [Related]
13. Expression of ADAM Proteases in Bladder Cancer Patients with BCG Failure: A Pilot Study.
Pichler R; Lindner AK; Schäfer G; Tulchiner G; Staudacher N; Mayr M; Comperat E; Orme JJ; Schachtner G; Thurnher M
J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33672843
[TBL] [Abstract][Full Text] [Related]
14. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer.
Gandhi NM; Morales A; Lamm DL
BJU Int; 2013 Aug; 112(3):288-97. PubMed ID: 23517232
[TBL] [Abstract][Full Text] [Related]
15. Relapse-Free Survival and PD-L1 Expression in First High- and Low-Grade Relapsed Luminal, Basal and Double-Negative P53-Mutant Non-Muscular Invasive Bladder Cancer Depending on Previous Chemo- and Immunotherapy.
Blinova E; Enikeev D; Roshchin D; Samyshina E; Deryabina O; Tertychnyy A; Blinov D; Kogan E; Dudina M; Barakat H; Merinov D; Kachmazov A; Serebrianyi S; Potoldykova N; Perepechin D
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455829
[TBL] [Abstract][Full Text] [Related]
16. Integrating the PD-L1 Prognostic Biomarker in Non-Muscle Invasive Bladder Cancer in Clinical Practice-A Comprehensive Review on State-of-the-Art Advances and Critical Issues.
Sanguedolce F; Falagario UG; Zanelli M; Palicelli A; Zizzo M; Busetto GM; Cormio A; Carrieri G; Cormio L
J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673455
[TBL] [Abstract][Full Text] [Related]
17. The effect of age on the efficacy of maintenance bacillus Calmette-Guérin relative to maintenance epirubicin in patients with stage Ta T1 urothelial bladder cancer: results from EORTC genito-urinary group study 30911.
Oddens JR; Sylvester RJ; Brausi MA; Kirkels WJ; van de Beek C; van Andel G; de Reijke TM; Prescott S; Witjes JA; Oosterlinck W
Eur Urol; 2014 Oct; 66(4):694-701. PubMed ID: 24948466
[TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy.
Rentsch CA; Birkhäuser FD; Biot C; Gsponer JR; Bisiaux A; Wetterauer C; Lagranderie M; Marchal G; Orgeur M; Bouchier C; Bachmann A; Ingersoll MA; Brosch R; Albert ML; Thalmann GN
Eur Urol; 2014 Oct; 66(4):677-88. PubMed ID: 24674149
[TBL] [Abstract][Full Text] [Related]
19. Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L; Cesson V; Lucca I; Cerantola Y; Valerio M; Fritschi U; Vlamopoulos Y; Burruni R; Legris AS; Dartiguenave F; Gharbi D; Martin V; Vaucher L; Speiser DE; Romero P; Jichlinski P; Nardelli-Haefliger D
Clin Cancer Res; 2017 Feb; 23(3):717-725. PubMed ID: 27521445
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of the Increase in Immunosuppressive Cell-Related Gene Expression in Urine Sediment during Intravesical Bacillus Calmette-Guérin.
Miyake M; Hori S; Ohnishi S; Owari T; Iida K; Ohnishi K; Morizawa Y; Gotoh D; Itami Y; Nakai Y; Inoue T; Anai S; Torimoto K; Aoki K; Fujii T; Tanaka N; Fujimoto K
Diseases; 2019 Jun; 7(2):. PubMed ID: 31216733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
